NASDAQ:CALC

CalciMedica Q1 2025 Earnings Results & Report

CalciMedica logo
$1.17 -0.05 (-4.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 -0.01 (-0.85%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CalciMedica beat analyst earnings expectations in its Q1 2025 results, released May 14, 2025. The company reported EPS of -$1.80 versus the -$2.15 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

CalciMedica EPS Results

Actual EPS
-$1.80
Consensus EPS
-$2.15
Beat/Miss
Beat by +$0.35
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

CalciMedica Q1 2025 Earnings FAQ

CalciMedica (NASDAQ:CALC) reported earnings of -$1.80 per share for Q1 2025, beating the consensus estimate of -$2.15. The report was announced on Wednesday, May 14, 2025.

CalciMedica Earnings Headlines

FY2026 EPS Estimates for CalciMedica Raised by HC Wainwright
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
CalciMedica (CALC) Set to Release Earnings on Wednesday
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC) is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immunologic conditions. Its research focuses on calcium release-activated calcium (CRAC) channels, which play a role in immune-cell activity and inflammation.

The company’s lead drug candidate, Auxora, is an investigational CRAC channel inhibitor being studied for acute inflammatory conditions, including acute pancreatitis. CalciMedica has no marketed products; its candidates remain in clinical development.

Based in La Jolla, California, CalciMedica became a publicly traded company in 2024 through a business combination with Orion Acquisition Corp. The company’s work is centered on developing and testing its therapies, rather than commercial product sales.

View CalciMedica Profile